Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The cytokines cardiotrophin-like cytokine/cytokine-like factor-1 (CLC/CLF) and ciliary neurotrophic factor (CNTF) differ in their receptor specificities.
Epistasis and immunity: the role of genetic interactions in autoimmune diseases.
Partnering to increase access to community exercise programs for people with stroke, acquired brain injury, and multiple sclerosis.
Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro.
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.
BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety.
Central nervous system lymphoma associated with natalizumab.
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
New Drug Review 2010: Ustekinumab (Stelara, Centocor Ortho Biotech)
The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?
Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy.
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group.
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
An Empirical Investigation of a Biopsychosocial Model of Pain in Multiple Sclerosis.
The natural course of clinically isolated syndrome in pediatric patients.
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination.
IFN-γ Signaling to Astrocytes Protects from Autoimmune Mediated Neurological Disability.
Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
CCSVI and MS: no meaning, no fact.
Extension Trial Data Shows Cladribine Benefits Persist in RRMS Patients
IL-1β induces hypomyelination in the periventricular white matter through inhibition of oligodendrocyte progenitor cell maturation via FYN/MEK/ERK signaling pathway in septic neonatal rats.
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning.
Multiple sclerosis: a primary care perspective.
Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Pages
« first
‹ previous
…
172
173
174
175
176
177
178
179
180
…
next ›
last »